🔎 Trials Near Me

Home › Parkinson's Disease › Pennsylvania › Pittsburgh

Parkinson's Disease clinical trials in Pittsburgh, PA

6 studies for Parkinson's Disease are looking for participants at sites in and around Pittsburgh (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

Stimulating Specific Brain Areas (VOP/VIM) With Electricity to Improve Movement and Muscle Control

Recruiting
  • University of Pittsburgh, Pittsburgh
Ages 18 to 75 · All sexes · Updated Sep 18, 2026 · NCT07056361

Parkinson's Foundation PD GENEration Genetic Registry

RecruitingObservational study
  • Allegheny Health Network, Pittsburgh
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT04994015

Deep Brain Stimulation (DBS) Retrospective Outcomes Study

RecruitingObservational study
  • Allegheny General Hospital, Pittsburgh
All ages · All sexes · Updated Sep 3, 2026 · NCT03664609

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

RecruitingPhase 3
  • Allegheny General Hospital, Pittsburgh
Ages 50 to 85 · All sexes · Updated Sep 3, 2026 · NCT07174310

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

RecruitingObservational studyHealthy volunteers welcome
  • University of Pittsburgh, Pittsburgh
Ages 30 and older · All sexes · Updated Jul 27, 2026 · NCT04477785

Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.

RecruitingPhase 1
  • UPMC Presbyterian Hospital, Pittsburgh
Ages 50 to 80 · All sexes · Updated May 4, 2026 · NCT07064005

About Parkinson's Disease

Parkinson's disease (PD) is a movement disorder. It causes tremors, stiffness, and slow movement. It gets worse over time. Learn what can help.

More about Parkinson's Disease on MedlinePlus

Parkinson's Disease trials in other cities

Other studies in Pittsburgh

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.